The Association of APOE Genotype with Cognitive Function in Persons Aged 35 Years or Older by Izaks, Gerbrand J. et al.
The Association of APOE Genotype with Cognitive
Function in Persons Aged 35 Years or Older
Gerbrand J. Izaks
1,2*, Ron T. Gansevoort
3, Aafke M. van der Knaap
4, Gerjan Navis
3, Robin P. F. Dullaart
4,
Joris P. J. Slaets
1,2
1University Center for Geriatric Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, 2Alzheimer Center Groningen,
University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, 3Department of Nephrology, University Medical Center Groningen, University
of Groningen, Groningen, The Netherlands, 4Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Abstract
APOE genotype is associated with the risk of Alzheimer’s disease. In the present study, we investigated whether APOE
genotype was associated with cognitive function in predominantly middle-aged persons. In a population-based cohort of
4,135 persons aged 35 to 82 years (mean age (SD), 55 (12) years), cognitive function was measured with the Ruff Figural
Fluency Test (RFFT; worst score, 0 points; best score, 175 points). APOE genotype (rs429358 and rs7412) was determined by
polymerase chain reaction. The mean RFFT score (SD) of the total cohort was 69 (26) points. Unadjusted, the mean RFFT
score in homozygous APOE e4 carriers was 4.66 points lower than in noncarriers (95% confidence interval, -9.84 to 0.51;
p=0.08). After adjustment for age and other risk factors, the mean RFFT score in homozygous APOE e4 carriers was 5.24
points lower than in noncarriers (95% confidence interval, -9.41 to -1.07; p=0.01). The difference in RFFT score was not
dependent on age. There was no difference in RFFT score between heterozygous APOE e4 carriers and noncarriers. The
results indicated that homozygous APOE e4 carriers aged 35 years or older had worse cognitive function than heterozygous
carriers and noncarriers.
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Introduction
It is well established that the risk of Alzheimer’s disease is
increased in APOE e4 carriers [1]. Probably, this is caused by
diverse pathogenic mechanisms as apolipoprotein E (ApoE) plays a
role in various processes in the brain including the production and
clearance of amyloid-b, and the maintenance and repair of
synapses and neurons [2]. As some of these processes occur at all
ages, it is likely that ApoE also contributes to structural and
functional changes in the brain of young persons. Therefore,
APOE genotype may be related to cognitive function many years
before cognitive impairment becomes clinically apparent.
Only a few studies on the relationship of APOE genotype with
cognitive function included young adults. Three studies were large
enough to examine the association between APOE genotype and
cognitive function in successive groups of age [3–6]. One study
showed no association of APOE genotype with cognitive function
in young adults [3,6], but two other studies found that APOE e4
carriers aged 40 years or older had worse cognitive function than
noncarriers of similar age. However, the latter studies were
performed in strongly selected populations with a relatively high
frequency of the APOE e4 allele [4,5]. More importantly, one of
the studies essentially included one extended family [4].
The aim of this study was to investigate the association of APOE
genotype with cognitive function in both young and older persons
from the general population. The study included 4,135 persons
who were aged 35 to 82 years.
Materials and Methods
Study population
The study population comprised all participants of the third
survey of the Prevention of Renal and Vascular ENd-stage Disease
study (PREVEND) that is being conducted in the city of
Groningen, the Netherlands. The PREVEND study was designed
to investigate prospectively the natural course of (micro)albumin-
uria and its relation to renal and cardiovascular disease in the
general population. Details of the study protocol have been
published elsewhere [7,8], and can be found at www. prevend.org.
The total cohort included 8,592 persons at baseline (1997–1998).
Of these, 8,574 persons completed the first survey and were
followed over time. The second survey was performed from 2001
to 2003 (N=6,894) and the third survey was performed from 2003
to 2006 (N=5,862); thus, compared to the cohort at baseline, the
participation rate was 80% and 68%, respectively.
Cognitive function
Cognitive function was measured with the Ruff Figural Fluency
Test (RFFT)[9,10]. The test was added to the measurements of
PREVEND in the third survey. The RFFT is a measure of
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function and is sensitive to early cognitive dysfunction [11]. The
RFFT has five parts and requires respondents to draw as many
different designs as possible within one minute per part by
connecting patterns of dots [10]. The RFFT is sensitive to changes
in executive function in both young and older persons [9,12]. The
main outcome measure of the RFFT is the total number of unique
designs, which varies from 0 points (worst score) to 175 points (best
score). In the PREVEND study, each RFFT was analyzed by two
trained and independent examiners (intraclass correlation coeffi-
cient, 1.00; 95%CI, 0.99 to 1.00)[12].
All 5,862 participants of the third survey of the PREVEND
study were required to perform the RFFT, and the test was
completed by 4,158 persons (71%). The RFFT scores of the other
1,704 persons (29%) were not known: 1,271 persons (22%) refused
to perform the RFFT, and 434 persons (7%) had missing RFFT
scores for other reasons.
Age and educational level
Age was defined as the age in full years on the date of
performance on the RFFT. Educational level was divided into four
groups according to the International Standard Classification of
Education (ISCED) [13]: primary school, ISCED 0 to 1 (0 to 8
years of education); lower secondary education, ISCED 2 (9 to 12
years of education); higher secondary education, ISCED 3–4 (13
to 15 years of education); university, ISCED 5 (16 or more years of
education).
APOE genotyping
Genotyping was performed at the University Medical Center
Groningen and at the Laboratory of Experimental Vascular
Medicine, Academic Medical Center Amsterdam, the Nether-
lands. DNA was extracted from whole blood using the Qiamp
mini kit (Qiagen). APOE genotypes (rs429358 and rs7412) were
determined by allelic discrimination on a TaqMan 7500 Real
Time PCR system, using the single-nucleotide polymorphism
(SNP) genotyping mixes C-3084793-20 and C-904973-10 and
Taqman Universal PCR mastermix No AmpErase (Applied
Biosystems, Nieuwerkerk a/d IJssel, the Netherlands). The method
has been validated against a previously described restriction
isotyping procedure [14,15]. Assays were carried out according to
the manufacturer’s recommendations on an ABI 7900HT
apparatus.
Other measurements
Cardiovascular risk factors were measured because they are
important non-genetic risk factors for Alzheimer’s disease and
cognitive decline [16]. Diabetes mellitus was defined as either a
fasting glucose equal to or greater than 7 mmol/L, or a non-
fasting glucose equal to or greater than 11.1 mmol/L, or the use of
glucose lowering drugs [17]. Smoking was defined as current
smoking or cessation of smoking less than one year before the
study. Body Mass Index (BMI) was calculated as weight in
kilograms divided by height in meters squared. Blood pressure was
automatically measured in supine position during ten minutes on
both visits. Blood pressure values are given as the mean of the last
two recordings of both visits. Plasma glucose and total cholesterol
were measured by dry chemistry (Eastman Kodak, Rochester,
NY). High density lipoprotein (HDL) cholesterol was measured
with a homogeneous method (direct HDL, Aeroset TM System,
Abbott Laboratories, Abbott Park, IL). Non-HDL cholesterol was
calculated as total cholesterol minus HDL cholesterol. Albumin-
uria was determined in two consecutive 24-hour urine samples by
nephelometry. Elevated albuminuria was defined as albuminuria
equal to or greater than 30 mg/day. A history of cardiovascular
and cerebrovascular events was defined as a prior cardiac or
cerebrovascular event for which subjects had been hospitalised.
Data on disease history were derived from a questionnaire at
baseline and during follow-up obtained from the Dutch national
registries of hospital discharge diagnoses and death certificates.
Data on drug use were obtained from the InterAction DataBase
(IADB; www.iadb.nl) of the departments of PharmacoEpidemiol-
ogy and PharmacoEconomics of the Groningen Graduate School
of Medical Sciences which comprises pharmacy-dispending data
of the community-pharmacists in the study region of the
PREVEND study [18].
Ethics statement
The PREVEND study has been approved by the Medical
Ethical Committee (METc) of the University Medical Center
Groningen, Groningen, the Netherlands, and is conducted in
accordance with the guidelines of the Declaration of Helsinki.
Written informed consent was obtained from all participants.
Statistical analysis
Differences in numerical variables were tested with the two-
tailed independent-samples t test or, if appropriate, one-way
analysis of variance. Differences in categorical variables were
tested by x
2 test or, if appropriate, Fisher exact test. The
association between RFFT score and APOE genotype was
analyzed by multiple linear regression analysis. APOE genotype
was entered in the regression model as two dummy variables:
APOE e4 heterozygosity (no/yes) and APOE e4 homozygosity (no/
yes). By definition, the noncarrier genotype was the reference
category. The regression model also included the variables age,
gender, educational level, diabetes mellitus, smoking status, BMI,
systolic blood pressure, glucose, HDL cholesterol, non-HDL
cholesterol, and elevated albuminuria. Interaction between APOE
genotype and age was tested by entering the product terms APOE
e4 heterozygosity x Age and APOE e4 homozygosity x Age in the
regression model. In all regression models, the variables age, BMI,
systolic blood pressure, glucose, HDL cholesterol and non-HDL
cholesterol were entered as continuous variables. All other
variables were entered as categorical variables. The level of
statistical significance was set at 0.05. Statistical analysis was done
with SPSS 16.0 for Windows (SPSS Inc., Chicago, IL).
Additional analyses
Due to its design, the total PREVEND cohort comprised a
relatively high number of persons with elevated albuminuria.
Because this may influence some data analyses, all analyses were
repeated in a representative sample of the Groningen population.
This so-called Groningen Random Sample is a subset of the total
PREVEND cohort, and was created by stratified random
sampling with strata based on albuminuria [7]. The prevalence
of albuminuria in the Groningen Random Sample is equal to the
prevalence in the general population. At the third survey, the
Groningen Random Sample included 2,404 persons.
Secondly, the analyses were repeated after exclusion of 172
persons (4%) of non-European descent. This group mainly
included persons of Asian descent but also 30 persons of African
descent (Table S1). Concordant with studies in populations of
African descent, the prevalence of the APOE e4 allele was
relatively high in this group (Table S2).
Thirdly, the analyses were repeated after exclusion of APOE e2/
e4 carriers because the APOE e2 allele is associated with protection
against Alzheimer’s disease [1], and the effect of the APOE e2/e4
genotype on cognitive function is unclear. The total study
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carriers, 30 (1%); e2/e3 carriers, 483 (12%); e2/e4 carriers, 92
(2%).
Finally, the analyses were repeated after exclusion of all APOE
e2 carriers.
Results
The RFFT was completed by 4,158 persons. Twenty persons
(0.5%) who completed the RFFT were excluded because their
educational level was not known and three persons (0.1%) were
excluded because their age was less than 35 years. Thus, the total
study population comprised 4,135 persons (Table 1).
The APOE genotype could be determined in 93% of the total
study population (Table 1). The frequency of the various APOE
genotypes was comparable to their frequency in other Dutch
populations [19,20]. Twenty-eight percent of the study population
was APOE e4 carrier of whom 2% was APOE e4 homozygous and
26% was APOE e4 heterozygous (Table 1). There was no
difference in genotype frequency between persons who performed
the RFFT and persons who did not perform the RFFT (data not
shown).
APOE genotype and cognitive function
RFFT scores were normally distributed and homozygous APOE
e4 carriers had lower RFFT scores than noncarriers. This
difference was observed across all ages (Figure 1). Overall, the
mean difference in RFFT score between homozygous APOE e4
carriers and noncarriers was 4.66 points (95% confidence interval,
-9.84 to 0.51; p=0.08). This could not be ascribed to differences in
demographic characteristics as there were no statistically signifi-
cant differences in age, gender and educational level between
homozygous APOE e4 carriers and noncarriers (Table 2; data for
separate age groups are reported in Table S3, S4, S5, S6, S7).
However, there were some differences in cardiovascular risk
factors. Homozygous APOE e4 carriers had lower HDL cholesterol
levels, and higher non-HDL cholesterol levels than noncarriers.
On the other hand, homozygous APOE e4 carriers had a lower
frequency of elevated albuminuria than noncarriers (Table 2).
There were no statistically significant differences for other
cardiovascular risk factors.
The difference in RFFT score between homozygous APOE e4
carriers and noncarriers was also found in multiple regression
analysis with adjustment for various covariables such as demo-
graphic characteristics and cardiovascular risk factors (Table 3). In
the fully adjusted model, the RFFT score in homozygous APOE e4
carriers was 5.24 points lower than in noncarriers (95% confidence
interval, -9.41 to -1.07; p=0.01). There was no interaction
between APOE genotype and age.
If homozygous APOE e4 carriers were compared with
heterozygous APOE e4 carriers, the mean RFFT score of
homozygous carriers was 6.81 points lower (95% confidence
interval, -12.15 to -1.47; p=0.01). There were some differences in
cardiovascular risk factors. The main difference was the higher
prevalence of elevated albuminuria in heterozygous carriers
(Table 2). After adjustment for the cardiovascular risk factors,
the RFFT score in homozygous APOE e4 carriers was 5.79 points
lower than in heterozygous carriers (95% confidence interval, -
10.71 to -5.12; p=0.008).
There was no difference in RFFT score between heterozygous
APOE e4 carriers and noncarriers. In most age groups,
heterozygous APOE e4 carriers even had a higher RFFT score
than noncarriers although the difference was small (Figure 1).
Here also, there were small differences in cardiovascular risk
factors between the groups (Table 2). However, adjustment for
various covariables did not yield different results. In the fully
adjusted model, RFFT scores in heterozygous APOE e4 carriers
and noncarriers were almost equal and the difference was not
statistically significant (Table 3).
Additional analyses
All additional analyses yielded essentially similar results.
Groningen Random Sample. This sample included 1,651
persons who performed the RFFT (69%). The APOE allele
frequencies were equal to the frequencies in the total cohort.
Unadjusted, the RFFT score in homozygous APOE e4 carriers was
7.32 points lower than in noncarriers (95% confidence interval, -
14.92 to 0.29; p=0.06). In the fully adjusted model, the RFFT
score in homozygous APOE e4 carriers was 5.78 points lower than
in noncarriers (95% confidence interval, -11.98 to 0.43; p=0.07).
There was no difference in RFFT score between heterozygous
APOE e4 carriers and noncarriers.
Exclusion persons of non-European descent. If the
persons of non-European descent were exluded from the
analysis, the unadjusted RFFT score in homozygous APOE e4
carriers was 4.44 points lower than in noncarriers (95% confidence
interval, -9.75 to 0.87; p=0.10). In the fully adjusted model, the
RFFT score in homozygous APOE e4 carriers was 5.11 points
lower than in noncarriers (95% confidence interval, -9.37 to -0.85;
p=0.02). There was no difference in RFFT score between
heterozygous APOE e4 carriers and noncarriers.
Table 1. Characteristics of the study population.
N (%) 4135 (100)
Gender, N (%)
Women 1978 (48)
Men 2157 (52)
Ethnicity
European 3963 (96)
Other 172 (4)
Age, mean (SD), y 55 (12)
Age, N (%), y
35–44 920 (22)
45–54 1277 (31)
55–64 1002 (24)
65–74 691 (17)
$75 245 (6)
Educational level, N (%)
Primary school 406 (10)
Lower secondary education 1225 (29)
Higher secondary education 1108 (27)
University 1396 (34)
APOE e4 genotype, N (%)
All 3855 (93)
Homozygous carrier (e4/e4) 101 (2)
Heterozygous carrier (e2/e4o re3/e4) 1065 (26)
Noncarrier 2689 (65)
RFFT score, mean (SD) 69 (26)
doi:10.1371/journal.pone.0027415.t001
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APOE e2/e4 carriers, the unadjusted RFFT in homozygous APOE
e4 carriers was 6.97 points lower than in heterozygous APOE e4
carriers (95% confidence interval, -12.32 to -1.62; p=0.01), and
4.66 points lower than in noncarriers (95% confidence interval, -
9.84 to 0.51; p=0.08). In the fully adjusted models, the RFFT
score in homozygous APOE e4 carriers was 5.72 points lower than
in heterozygous APOE e4 carriers (95% confidence interval, -9.99
to -1.45; p=0.009), and 5.23 points lower than in noncarriers
(95% confidence interval, -9.67 to -1.39; p=0.009).
In addition, the unadjusted RFFT score in heterozygous APOE
e4 carriers was 2.31 points higher than in noncarriers (95%
confidence interval, 0.41 to 4.22; p=0.02). In the fully adjusted
model, heterozygous APOE e4 carriers and noncarriers had similar
RFFT scores (mean difference, 0.96 points; 95% confidence
interval, -0.58 to 2.51; p=0.22).
Exclusion of all APOE e2 carriers. After exclusion of all
APOE e2 carriers, the unadjusted RFFT score in homozygous
APOE e4 carriers was 4.98 points lower than in noncarriers (95%
confidence interval, -10.17 to 0.21; p=0.06). In the fully adjusted
model, the RFFT score in homozygous APOE e4 carriers was 7.91
points lower than in noncarriers (95% confidence interval, -12.46
to -3.36; p=0.001). Similar differences were found if homozygous
APOE e4 carriers were compared with heterozygous APOE e4
carriers. There was no difference in RFFT score between
heterozygous APOE e4 carriers and noncarriers.
Discussion
In this study, APOE e4 homozygous carriers had worse cognitive
function than APOE e4 heterozygous carriers and noncarriers.
This was not only found in older persons but across all ages
beginning at the age of 35 years. Remarkably, there was no
difference in cognitive function between APOE e4 heterozygous
carriers and noncarriers. Thus, the effect of the APOE e4 allele on
cognitive function was not dose-dependent in this study.
There are several studies on the association of APOE genotype
with cognitive function in young as well as older persons, but to
our knowledge, only three studies had sample sizes that were large
enough to draw reliable conclusions [3–6]. In one study, that was
part of a community survey and included persons who were 20 to
64 years of age [3,6], APOE genotype was not associated with
cognitive function. Surprisingly, this lack of association was not
only found in the young age groups but also in the old age group.
The authors suggested that the effects of APOE genotype only
occur above the age of 65 years but this explanation does not seem
Figure 1. RFFT score dependent on APOE e4 genotype and age. For clarity, data are presented as mean and 95% confidence interval of ten-
year age groups.
doi:10.1371/journal.pone.0027415.g001
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studies. The two other studies included persons aged 21 years or
older but were performed in selected subjects as one study sample
essentially consisted of one extended family [4],and the other study
sample was strongly enriched for APOE e4 carriers [5]. In these
studies, cognitive function of APOE e4 carriers and noncarriers was
comparable when they were aged 40 years or younger. The
difference in cognitive function between APOE e4 carriers and
noncarriers became first detectable between the ages of 40 and 55
years and then gradually increased with increasing age. In
contrast, in our community-based study, the difference in cognitive
function between APOE e4 homozygous carriers and noncarriers
was found in young as well as older persons, and the magnitude of
the difference in cognitive performance was similar across all ages.
Possibly, the differences in findings between our study and the
other two positive studies can be explained by the difference in
cognitive domains that were tested.
In the other two positive studies, APOE e4 carriers were
different from noncarriers if cognitive function was measured with
a verbal learning test [4,5]. In contrast to verbal learning, (figural)
fluency is dependent on cognitive abilities such as reaction time,
pattern recognition and problem solving. Verbal learning and
fluency have also been related to different brain regions. Whereas
verbal learning is usually associated with the hippocampus and
Table 2. Demographic characteristics and major cardiovascular risk factors dependent on APOE e4 genotype.
Homozygous carrier Heterozygous carrier Noncarrier p
N 101 1065 2689 N/A
Gender, N (%)
Women 47 (47) 500 (47) 1312 (49) 0.56
Men 54 (53) 565 (53) 1377 (51)
Age, mean (SD), y 54 (11) 54 (12) 55 (12) 0.07
Age, N (%), y
35–44 23 (23)
a 256 (24)
a 568 (21)
45–54 29 (29)
a 331 (31)
a 820 (31) 0.59
55–64 28 (28)
a 247 (23)
a 688 (25)
65–74 17 (17)
a 147 (16)
a 466 (17)
$75 4 (4)
a 57 (5)
a 167 (6)
Educational level, N (%)
Primary school 8 (8)
a 104 (10) 271 (10)
Lower secondary education 37 (37)
a 302 (28) 795 (30) 0.58
Higher secondary education 29 (29)
a 289 (27) 725 (27)
University 27 (27)
a 370 (35) 898 (33)
Cardiovascular risk factors
Diabetes mellitus, N (%) 3 (3) 72 (7) 163 (6) 0.29
Current smoker, N (%)
d 25 (25) 226 (21) 658 (25) 0.09
Body Mass Index, mean (SD), kg/m
2 26 (3) 27 (4) 27 (4) 0.08
Systolic blood pressure, mean (SD), mmHg 125 (17) 126 (18) 126 (18) 0.87
Glucose, mean (SD), mmol/L
b 4.8 (0.8) 4.9 (0.9) 4.9 (1.0) 0.79
Total cholesterol, mean (SD), mmol/L
c 5.60 (1.10) 5.41 (1.07) 5.35 (1.05) 0.02
HDL cholesterol, mean (SD), mmol/L
c 1.36 (0.41) 1.37 (0.38) 1.43 (0.38) ,0.001
Non-HDL cholesterol, mean (SD), mmol/L
c 4.24 (0.99) 4.04 (1.03) 3.92 (1.02) ,0.001
Elevated albuminuria, N (%)
d 6 (6) 151 (14) 402 (15) 0.04
History, N (%)
Coronary heart disease 3 (3.0) 54 (5.1) 97 (3.6) 0.10
Cerebrovascular disease 1 (1.0) 11 (1.0) 21 (0.8)
e
Current medication, N (%)
d
Blood pressure lowering agents 17 (20) 239 (30) 615 (30) 0.15
Lipid lowering agents 16 (19) 182 (23) 345 (17) 0.001
N/A, not applicable; SD, standard deviation.
aSum of the percentages is not equal to 100 due to rounding.
bMultiply by 18 to convert to mg/dL.
cMultiply by 39 to convert to mg/dL.
dDifferent total number due to missing data. For homozygous carriers, heterozygous carriers and noncarriers, data on smoking status were complete for 100, 1063, and
2671 persons, respectively; data on albuminuria were complete for 100, 1054, and 2667 persons, respectively; data on current medication were complete for 84, 792,
and 2053 persons, respectively.
eSuppressed because of expected cell count of less than 1.
doi:10.1371/journal.pone.0027415.t002
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prefrontal lobes [21,22]. However, genetic effects may vary
between brain regions [23]. Therefore, the difference in
association of APOE genotype with performance on verbal
learning and fluency tests may be due to a different effect of
ApoE on the medial temporal and prefrontal lobes.
The effectof ApoE on cognitive functionis commonly ascribed to
its role in the accumulation of amyloid-b in the brain [2]. However,
APOE e4 carriers and noncarriers do not clearly differ in this aspect
until the age of 50 to 59 years [24]. As a consequence, our findings
can not be explained by differences in amyloid-b accumulation
because in our study, the difference in cognitive function between
APOEe4carriersand noncarrierswasalreadypresentbeforetheage
of 50 years. An alternative explanation for the difference in
cognitive function at a relatively young age can be sought in the role
ofApoEinthegrowthand developmentofthebrain.ApoEmay,for
example, interfere with the binding of reelin to ApoE receptors, a
pathway that is crucial for neuronal migration and dendritic spine
development [2]. This mechanism may not only affect the
development of gray matter but also the development of white
matter. White matter is essential for brain connectivity and
integrates gray matter regions into neural networks [25]. More
importantly, white matter lesions are in general more related to
impairmentofcognitiveabilitiesthatareessentialforfluencythanto
memory dysfunction [26,27]. Interestingly, it was recently found
that APOE genotype dependentdifferencesinwhitematterstructure
are already present in young adulthood and do not undergo
significant differential changes with age [28].
Although there was a difference between APOE e4 carriers and
noncarriers in performance on a verbal learning test in the previous
studies, no differences were found on tests of other (nonmemory)
cognitive domains [4,5]. Some of these tests, such as the Trail
Making Test and the Stroop Color-Word Test [29,30], are
generally seen as a measure of executive function and thus reflect
similar cognitive abilities as the RFFT, that was used in our study.
Therefore, it can be questioned why no association of APOE
genotype with performance on these tests was found in the previous
studies. In fact, it does not seem plausible that a genotype that is
associated with an increased risk of Alzheimer’s disease is not
associated with decreased performance in other cognitive domains
as by definition, Alzheimer’s disease affects more than one cognitive
domain[31]. A possible explanation for the divergent finding on the
association of APOE genotype with performance on executive
function tests may be that the RFFT with its score range of 0 to 175
points is more sensitive to differences in performance than the tests
that were use in the other studies.
Another important difference between the studies was the effect
of APOE e4 heterozygosity. In the previous studies, APOE e4
heterozygous carriers had better cognitive function than APOE e4
homozygous carriers but worse cognitive function than non-
carriers. In our study, the cognitive function of APOE e4
heterozygous carriers was similar to that of the noncarriers. If it
is assumed that ApoE plays a role in the growth and development
of certain brain regions, this would mean that growth and
development of these regions is only affected if persons have two
APOE e4 alleles and not if persons have only one APOE e4 allele.
Homozygous APOE e4 carriers only express the ApoE4 isoform
of apolipoprotein E but heterozygous APOE e4 carriers also
express the ApoE2 or ApoE3 isoform. These other isoforms of
apoliprotein E are more effective in regulating brain lipid
metabolism and synaptic functions. ApoE3, for example, is more
effective than ApoE4 in transporting cholesterol in the brain and
in maintaining neurons [2]. Interestingly, it was found in brain
imaging studies that homozygous APOE e4 carriers have
considerably more white matter lesions than heterozygous APOE
e4 carriers and noncarriers whereas the load of white matter
lesions in heterozygous APOE e4 carriers and noncarriers was
comparable [32,33]. Thus, the presence of one other ApoE
Table 3. Multiple linear regression analysis of RFFT score on APOE e4 genotype.
Model 1
b Model 2
c Model 3
d Model 4
e
B SE(B) b p B SE(B) b p B SE(B) b p B SE(B) b p
APOE e4 genotype
Noncarrier aaaa
Heterozygous carrier 2.15 0.94 0.04 0.02 1.05 0.81 0.02 0.19 1.02 0.75 0.02 0.17 1.00 0.77 0.02 0.19
Homozygous carrier -4.66 2.64 -0.03 0.08 -5.83 2.26 -0.04 0.01 -4.61 2.09 -0.03 0.03 -5.24 2.13 -0.03 0.01
Age, y - - - -1.17 0.03 -0.52 ,0.001 -0.92 0.03 -0.41 ,0.001 -0.89 0.04 -0.40 ,0.001
Gender
M a n - - - aaa
Woman - - - -0.71 0.72 -0.13 0.33 0.38 0.67 0.007 0.57 -0.45 0.77 -0.009 0.56
Educational level
Primary school - - - -
- -a a
Lower secondary education - - - -
- - 6.66 1.23 0.12 ,0.001 5.67 1.26 0.10 ,0.001
Higher secondary education - - - - - - 14.89 1.28 0.25 ,0.001 13.54 1.31 0.23 ,0.001
University - - -
- - - 25.22 1.25 0.46 ,0.001 23.13 1.31 0.42 ,0.001
RFFT, Ruff Figural Fluency Test; B, unstandardized coefficient; SE(B), standard error of B; b, standardized coefficient.
aReference category
bAdjusted R
2, 0.002; residual standard deviation, 26.
cAdjusted R
2, 0.27; residual standard deviation, 22.
dAdjusted R
2, 0.37; residual standard deviation, 21.
eAdjusted for the covariates in model 3 plus diabetes mellitus, current smoking status, body mass index, systolic blood pressure, glucose, HDL cholesterol, and elevated
albuminuria. Adjusted R
2, 0.38; residual standard deviation, 21.
doi:10.1371/journal.pone.0027415.t003
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maintenance of the brain.
There are some methodological aspects to our study that need
to be acknowledged. First, the cross-sectional design may be
considered as a limitation. In general, one should be cautious
about inferring a causal relationship from a cross-sectional study.
However, APOE genotype is a proven risk factor for Alzheimer’s
disease and cognitive impairment in old age [1]. Consequentially,
it is unlikely that we observed a difference in cognitive
performance between homozygous APOE e4 carriers and
noncarriers when in truth there was none. Second, it should be
mentioned that we used only one test of cognitive function. Even
so, the RFFT score is the outcome of many different cognitive
abilities. Moreover, the RFFT is a sensitive cognitive test so that it
was possible to measure differences in cognitive performance in
relatively young persons. Additionally, in contrast to many other
tests, the RFFT does not seem to exhibit a strong floor or ceiling
effect as it has a wide range of scores. Third, due to the design of
the PREVEND study, the study sample included a relatively high
proportion of persons with elevated albuminuria and hence, with
increased cardiovascular risk. However, similar results were found
when the analyses were repeated in a random sample from the
general population. Finally, we did not conduct a replication
analysis because no independent replication cohort was available.
Therefore, our findings should be interpreted with some caution.
In conclusion, homozygous APOE e4 carriers aged 35 years and
older had worse cognitive function than heterozygous APOE e4
carriers and noncarriers of comparable age. The difference in
cognitive performance was not dependent on age and its
magnitude was similar for all ages.
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